Cart
×
This study is currently recruiting participants.
https://clinicaltrials.gov/ct2/show/NCT01826474?term=pro045&rank=1
The purpose of the study is to see whether PRO045 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA for the dystrophin protein.
Condition | Intervention | Phase |
---|---|---|
Duchenne Muscular Dystrophy | Drug: PRO045, 0.15 mg/kg/week Drug: PRO045, 1.0 mg/kg/week Drug: PRO045, 3.0 mg/kg/week Drug: PRO045, 6.0 mg/kg/week Drug: PRO045, 9.0 mg/kg/week Drug: PRO045, selected dose |
Phase 1 Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy |